Literature DB >> 11810672

Detection of lymph node metastases by contrast-enhanced MRI in an experimental model.

Patrick Wunderbaldinger1, Lee Josephson, Christoph Bremer, Anna Moore, Ralph Weissleder.   

Abstract

Lymph node size, the accumulation of a nodal lymphotrophic contrast agent (LCDIO), and MRI were compared as methods for detecting nodal metastases in an experimental murine model. Lymph node metastases (B16-F1 melanoma expressing green fluorescent protein (GFP) and C57BL/6 mice) were generated to obtain a wide spectrum of nodes, including normal nodes and nodes bearing micrometastases, small metastases, or large metastases. Nodal uptake of LCDIO was measured using (111)Indium-labeled LCDIO and was found to be lower in micrometastastic nodes (4.20 +/- 1.4%ID/gm) than in normal nodes (8.60 +/- 0.22% ID dose/gram, P < 0.005). Nodal tumor burden was quantified from the amount of GFP present in nodes measured using the Western blot method, and was found to correlate with the decrease of LCDIO uptake. By MRI, nodes bearing small and large metastases contained regions of high signal intensity (SI) that corresponded to the visual pattern of tumor in nodes. Micrometastatic nodes were distinguishable from normal nodes based on a diffuse pattern of inhomogeneous SI. The signal-to-background ratio (SBR) of normal nodes (0.0112 +/- 0.0061) was different from micrometastatic nodes (0.179 +/- 0.080, P < 0.00046) and nodes bearing small metastases (0.723 +/- 0.269, P < 0.00013), with high degrees of significance. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 11810672     DOI: 10.1002/mrm.10068

Source DB:  PubMed          Journal:  Magn Reson Med        ISSN: 0740-3194            Impact factor:   4.668


  30 in total

1.  Fluorescent nanoparticle uptake for brain tumor visualization.

Authors:  Rachel Tréhin; Jose-Luiz Figueiredo; Mikael J Pittet; Ralph Weissleder; Lee Josephson; Umar Mahmood
Journal:  Neoplasia       Date:  2006-04       Impact factor: 5.715

Review 2.  [Molecular and parametric imaging with iron oxides].

Authors:  L Matuszewski; B Tombach; W Heindel; C Bremer
Journal:  Radiologe       Date:  2007-01       Impact factor: 0.635

3.  Utility of a new bolus-injectable nanoparticle for clinical cancer staging.

Authors:  Mukesh Harisinghani; Robert W Ross; Alexander R Guimaraes; Ralph Weissleder
Journal:  Neoplasia       Date:  2007-12       Impact factor: 5.715

Review 4.  Unmet needs in the prediction and detection of metastases in prostate cancer.

Authors:  Oliver Sartor; Mario Eisenberger; Michael W Kattan; Bertrand Tombal; Frederic Lecouvet
Journal:  Oncologist       Date:  2013-05-06

Review 5.  Imaging macrophages with nanoparticles.

Authors:  Ralph Weissleder; Matthias Nahrendorf; Mikael J Pittet
Journal:  Nat Mater       Date:  2014-02       Impact factor: 43.841

Review 6.  Defining the role of modern imaging techniques in assessing lymph nodes for metastasis in cancer: evolving contribution of PET in this setting.

Authors:  Thomas C Kwee; Sandip Basu; Drew A Torigian; Babak Saboury; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-01-12       Impact factor: 9.236

Review 7.  Nanotechnology and its use in imaging and drug delivery (Review).

Authors:  Serjay Sim; Nyet Kui Wong
Journal:  Biomed Rep       Date:  2021-03-05

8.  Using carbon magnetic nanoparticles to target, track, and manipulate dendritic cells.

Authors:  Heidi A Schreiber; Jozsef Prechl; Hongquan Jiang; Alla Zozulya; Zsuzsanna Fabry; Ferencz Denes; Matyas Sandor
Journal:  J Immunol Methods       Date:  2010-02-26       Impact factor: 2.303

9.  Heat-induced radiolabeling and fluorescence labeling of Feraheme nanoparticles for PET/SPECT imaging and flow cytometry.

Authors:  Hushan Yuan; Moses Q Wilks; Marc D Normandin; Georges El Fakhri; Charalambos Kaittanis; Lee Josephson
Journal:  Nat Protoc       Date:  2018-01-25       Impact factor: 13.491

Review 10.  Nanotechnology in urology.

Authors:  Shihua Jin; Vinod Labhasetwar
Journal:  Urol Clin North Am       Date:  2009-05       Impact factor: 2.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.